Key Takeaway: Xtant Medical has announced definitive agreements for the sale of its Coflex® and CoFix® spinal implants, along with all international businesses, to Companion Spine. This transaction, valued at approximately $19.2 million, is expected to allow Xtant to concentrate more on its core operations while reducing debt and improving liquidity.
Price reaction · baseline $0.67 (2025-07-07 close) · hit pre-market · clean, no other XTNT news in the window
day 0 close · peak
-4.5%
Market Sentiment Analysis
POSITIVE FACTORS
Transaction enhances focus on core businesses.
Total consideration of approximately $19.2 million.
Reduction of outstanding debt improves liquidity.
Full Press Release Details
Transaction expected to facilitate enhanced focus on Xtant’s core businesses Total consideration of approximately $19.2 million allows Xtant to reduce outstanding debt and improve liquidity BELGRADE, Mont. , July 8, 2025 /PRNewswire/ — Xtant Medical Holdings, Inc.
Frequently Asked Questions
What companies are involved in the transaction?
The transaction involves Xtant Medical and Companion Spine.
What is the total consideration for the sale?
The total consideration for the sale is approximately $19.2 million.
What will Xtant Medical focus on after the sale?
Xtant Medical will enhance its focus on its core businesses.
How will the sale affect Xtant's financials?
The sale will help reduce outstanding debt and improve liquidity.